FDA Determines Regulatory Review Period for BLINCYTO Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for BLINCYTO, a human biological product, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).